Neuroendocrine Carcinoma (NEC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Neuroendocrine Carcinoma Emerging Therapy and TPP Insights

Thelansis’s “Neuroendocrine Carcinoma (NEC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Neuroendocrine Carcinoma (NEC) Overview

Neuroendocrine carcinoma (NEC) is a rare, highly aggressive, poorly differentiated cancer characterized by rapid proliferation and early metastatic spread, distinct from well-differentiated neuroendocrine tumors. Pulmonary and extrapulmonary NECs commonly show high Ki-67 indices and frequent alterations in TP53 and RB1, while diagnosis integrates morphology with neuroendocrine markers such as synaptophysin and INSM1. Treatment depends strongly on tumor site: for extensive-stage small-cell lung cancer, platinum-etoposide combined with atezolizumab or durvalumab is an established frontline approach, whereas extrapulmonary NEC generally relies on platinum-based chemotherapy, with immunotherapy considered selectively according to tumor biology and available evidence. The relapsed setting remains challenging, but precision approaches are expanding. Tarlatamab, a DLL3×CD3 bispecific T-cell engager, has demonstrated meaningful activity in refractory SCLC and is FDA-approved for extensive-stage SCLC after platinum therapy, while DLL3-directed strategies are being investigated in extrapulmonary NEC. For stakeholders, NEC illustrates the challenge of translating a shared aggressive biology into site-specific treatment strategies.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)